Non Hodgkin Lymphoma Clinical Trial
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving fenretinide in a different way may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating patients with refractory or relapsed hematologic cancer.
Full Description
OBJECTIVES:
Determine the maximum tolerated dose of intravenous emulsified fenretinide in patients with refractory or relapsed hematologic malignancies.
Determine the toxic effects of this drug in these patients.
Determine the pharmacokinetics and in vivo activity of this drug in these patients.
Determine, preliminarily, disease or tumor response in patients treated with this drug.
OUTLINE: This is a pilot, dose-escalation, multicenter study.
Patients receive emulsified fenretinide IV continuously over 5 days. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete or partial response may continue to receive fenretinide at the discretion of the study chair.
Cohorts of 1 patient receive accelerated escalating doses of fenretinide until 2 patients experience moderate toxicity (cumulative across all dose levels) OR 1 patient experiences dose-limiting toxicity (DLT). After completion of the accelerated dose-escalation portion, the standard dose-escalation portion begins. Cohorts of 3-6 patients receive escalating doses of fenretinide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. At least 6 patients are treated at the MTD. An additional 12 patients are treated at the MTD.
After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed diagnosis of 1 of the following hematologic malignancies:
Non-Hodgkin's lymphoma (NHL)
Hodgkin's lymphoma
Multiple myeloma
Acute lymphoblastic leukemia
Acute myeloid leukemia
Chronic hematologic malignancy with a poor prognosis (e.g., failed 3 prior standard therapies), including any of the following:
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Indolent NHL
Myeloproliferative disorders
Refractory or relapsed disease, as defined by 1 of the following:
Resistant to standard therapy for refractory or relapsed disease
Progressed after standard therapy for advanced disease
No effective treatment exists
Measurable or evaluable disease
No active CNS disease
Previously treated leptomeningeal disease or brain metastases allowed provided there is no evidence of remaining cancer by positron-emission tomography, MRI, or spinal fluid cytology
PATIENT CHARACTERISTICS:
Age
18 and over
Performance status
ECOG 0-2
Life expectancy
At least 3 months
Hematopoietic
Absolute neutrophil count ≥ 1,500/mm^3 (unless due to bone marrow involvement of disease)
Platelet count ≥ 75,000/mm^3 (unless due to bone marrow involvement of disease)
Hemoglobin ≥ 8.0 g/dL (transfusion allowed)
No coagulation disorders
Hepatic
AST and ALT < 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for patients with liver metastasis)
Bilirubin ≤ 1.5 times ULN
Renal
Creatinine ≤ 1.5 times ULN
Cardiovascular
No major cardiovascular disease
Pulmonary
No major respiratory disease
Other
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective double-method contraception prior to study entry, during study, and for at least 6 months after study participation
No uncontrolled systemic infection
No uncontrolled hypertriglyceridemia (i.e., triglyceride level > 500 mg/dL)
No known HIV positivity
No known allergy to egg products
No known familial hyperlipidemia disorders
No previously undiscovered hypertriglyceridemia
No poorly controlled diabetes
PRIOR CONCURRENT THERAPY:
Biologic therapy
Not specified
Chemotherapy
More than 2 weeks since prior chemotherapy except hydroxyurea
No concurrent hydroxyurea during study drug administration
No other concurrent anticancer chemotherapy
Endocrine therapy
No concurrent hormone-ablative agents
No concurrent steroids
No concurrent tamoxifen or any of its analogues
Radiotherapy
No prior cranial radiotherapy
More than 2 weeks since prior radiotherapy
Surgery
More than 20 days since prior surgery except for biopsy
Other
Recovered from all prior therapy
More than 2 weeks since prior investigational agents
No other concurrent investigational agents
No other concurrent antineoplastic therapy
No other concurrent antioxidants
No concurrent herbal or other alternative therapies
No concurrent vitamin supplements (e.g., vitamin A, ascorbic acid, or vitamin E)
Standard dose multivitamin allowed
No other concurrent medications that may act as modulators of intracellular ceramide levels or ceramide cytotoxicity, sphingolipid transport, or p-glycoprotein or multidrug resistance protein 1 (MRP1) drug/lipid transporters, including any of the following:
Cyclosporine or any of its analogues
Verapamil
Ketoconazole
Chlorpromazine
Mifepristone
Indomethacin
Sulfinpyrazone
No concurrent medications that may cause pseudotumor cerebri, including any of the following:
Tetracycline
Nalidixic acid
Nitrofurantoin
Phenytoin
Sulfonamides
Lithium
Amiodarone
No concurrent medication to control hypertriglyceridemia
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Los Angeles California, 90089, United States
Bethesda Maryland, 20892, United States
Houston Texas, 77030, United States
Lubbock Texas, 79410, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.